INTRODUCTION
Current models view the Myc oncoprotein as a central regulator that stimulates cell growth and cell proliferation in response to extracellular signals. Myc exerts this control at least in part, since it binds to specific DNA sequences and affects the transcription of multiple genes involved in protein synthesis, metabolism, and cell proliferation (Eilers and Eisenman, 2008) .
Consequently, a large body of research has identified mechanisms that control expression of Myc in response to growth factor-dependent signals. For example, transcription from the MYC promoter is enhanced by transcription factors including Ets-1 and E2F1 that are regulated by mitogen-activated protein kinases and cyclin-dependent kinases, respectively (Roussel et al., 1994) . Similarly, a b-catenin/TCF site mediates induction of the MYC promoter in response to the Wnt signaling pathway . In addition, growth factor-dependent stimulation of PI3-kinase protects the Myc protein from proteasomal degradation (Sears et al., 2000) . Conversely, a repressor complex containing Smad and E2F4 that forms on the MYC promoter in response to TGFb represses Myc expression and mediates the antiproliferative effects of this cytokine (Chen et al., 2002) .
Elevated levels of Myc not only induce growth and proliferation but also strongly sensitize cells toward proapoptotic stimuli including DNA damaging agents (Maclean et al., 2003) . Consequently, downregulation of Myc is essential to ensure cell cycle arrest and survival of cells in response to DNA damaging agents (Cannell et al., 2010) . Similarly, the ability to downregulate Myc in the presence of strong mitogenic signals is required for oncogene-induced senescence and may therefore constitute a tumor-suppressive mechanism (Hydbring et al., 2010) . Finally, specific cell populations such as stem cells restrict Myc expression despite the presence of multiple growth factors and cytokines that would be expected to stimulate Myc expression and exit from quiescence (Laurenti et al., 2009 ). These observations argue that mechanisms that limit Myc expression need to be dominant in specific conditions to ensure cellular survival and organismal homeostasis.
Negative feedback regulation plays a key role in restricting Myc levels in nontransformed cells. Initial evidence supporting this notion comes from observations that document repression of endogenous MYC mRNA whenever an ectopic Myc transgene is introduced into normal cells (Penn et al., 1990) . Negative feedback regulation is frequently disrupted during oncogenic transformation, enabling transformed cells to express elevated levels of Myc. The molecular mechanism(s) underlying this control and its disruption during transformation are poorly understood. One mechanism involves regulation of the MYC (P2) promoter by Myc (Penn et al., 1990) . A) Depletion of MK5 increases Myc protein levels. The indicated cell lines were mock-transfected (À) or transfected with siRNA targeting MK5 (siMK5) or a control siRNA (siCtr). Seventy-two hours after transfection, MK5 and Myc levels were determined by immunoblotting. b-actin was used as control for equal loading in all experiments. Numbers below each blot indicate the levels of Myc relative to control cells. (B) Depletion of MK5 increases levels of Myc protein, but not MYC mRNA. U2OS cells were transfected with a pool of four independent siRNAs targeting siMK5 (a-d) or each of the individual siRNA oligonucleotides. Three days after transfection, Myc protein levels were determined by immunoblotting (upper panel). MYC mRNA levels were assessed by RQ-PCR analysis (lower panel) and are presented as mean + standard deviation (SD) (n = 3). (C) MK5 decreases Myc protein levels. HeLa cells were transiently transfected with CMV-driven expression vectors encoding wild-type MK5 (WT), a kinase-inactive mutant (K51M), or two constitutively active MK5 mutants (T182D, L337G) or an empty vector control (À). Forty-eight hours after transfection, MK5 and Myc protein levels were determined by immunoblotting. MK5 kinase activity is stated above the MK5 blot (À for kinase-inactive, + and ++ for increased kinase activity). More recently, microRNAs have emerged as central players in networks that establish regulatory circuits. We have recently identified a p53-independent pathway that involves miR-34 and that is critical for downregulation of Myc in response to the DNA damaging agent etoposide (Cannell et al., 2010) . Using high-content microscopy, we have now performed an siRNA screen of the human kinome and identified MK5 as a negative regulator of Myc expression. We show here that MK5, FoxO proteins, and miR-34 take part in a negative feedback loop that controls Myc expression and that is disrupted during colorectal carcinogenesis.
RESULTS
In order to identify kinases that regulate expression of Myc at a posttranscriptional level, we generated a U2OS osteosarcoma cell line that expresses the MYC mRNA under the control of the retroviral LTR and performed an siRNA screen of the human kinome using high-content microscopy (see Figure S1 available online). We found a small group of siRNAs that reproducibly affected levels of Myc in this assay and focus here on MAPKAPK5 (MK5, PRAK).
Transfection of siRNA targeting MK5 enhanced expression of endogenous Myc in osteosarcoma (U2OS), cervical carcinoma (HeLa), and colon carcinoma (HCT116) cells, demonstrating that regulation of Myc levels did not occur via the retroviral LTR and was not restricted to a specific cell type ( Figure 1A ). To rule out off-target effects, we tested the four siRNAs contained in the pool that was used in the siRNA screen individually and found that each of them reduced expression of MK5 and enhanced expression of Myc to a similar extent ( Figure 1B) . Furthermore, infection of U2OS cells with two distinct retroviruses that express shRNAs targeting MK5 led to a decrease in MK5 expression and enhanced Myc levels ( Figure S2A ). To test whether enhanced expression of MK5 reduces expression of Myc, we transfected HeLa cells with expression vectors encoding either wild-type MK5, a kinase-dead allele of MK5 (K51M), or two alleles that have elevated kinase activity (T182D, L337G) (Seternes et al., 2002) . Ectopic expression of MK5T182D or of MK5L337G decreased levels of endogenous Myc, whereas expression of wild-type or kinase-dead alleles of MK5 had no effect ( Figure 1C ). Ectopic expression of a mutated allele of MK5L337G that is resistant to siRNA targeting MK5 also abolished induction of Myc expression by siMK5, demonstrating that the effect of the siRNA is an on-target effect ( Figure S2B ). Consistent with a role as a negative regulator of Myc, expression of active MK5 strongly suppressed proliferation of U2OS cells ( Figure 1D ). Taken together, our data show that active MK5 kinase suppresses Myc expression in human tumor cells.
We performed a number of experiments to analyze how MK5 regulates expression of Myc. RQ-PCR analyses showed that depletion of MK5 using either siRNA or retroviral expression of shRNA had only small effects on levels of MYC mRNA ( Figure 1B ; Figure S2A ). Therefore, we ruled out models in which MK5 affects Myc expression via transcriptional upregulation of the MYC promoter. To measure turnover of Myc, we transfected HeLa cells with either control siRNA or siRNA depleting MK5. Seventy-two hours later, we added cycloheximide to block protein synthesis and obtained cell lysates at different times afterwards. While depletion of MK5 led to elevated levels of Myc, there was no difference in Myc turnover between control and MK5-depleted cells ( Figure 1E ). Finally, we pulse labeled control and MK5-depleted cells with 35 S-methionine for 60 min to label newly synthesized proteins; subsequently, we precipitated lysates with control or a-Myc antibodies ( Figure 1F ). Depletion of MK5 led to an enhanced incorporation of label into newly synthesized Myc protein but had no effect on total protein synthesis (data not shown). We concluded that MK5 is a negative regulator of MYC translation.
To understand how MK5 affects translation of Myc, we generated a series of constructs that encompass either the entire MYC mRNA, only the coding sequence, or the coding sequence and the 5 0 UTR or the 3 0 UTR, respectively ( Figure 2A ). All constructs were stably expressed via retroviral infection of U2OS cells; subsequently, pools of cells were transfected with either control or siRNA targeting MK5. Depletion of MK5 enhanced levels of endogenous Myc, as before. Ectopic expression of constructs that encompass either the coding sequence or the coding sequence and the 5 0 UTR led to strongly elevated levels of Myc that were not further enhanced by depletion of MK5. In contrast, the expression of MYC constructs that encompass the 3 0 UTR led to moderately elevated levels of Myc that were further enhanced by depletion of MK5, demonstrating that the 3 0 UTR represses expression of Myc in an MK5-dependent manner.
The 3 0 UTR of Myc contains a binding site for the miR-34 family of miRNAs, suggesting that MK5 might regulate Myc expression via one or several members of the miR-34 family. The family consists of three members, termed miR-34a, -b, and -c, two of which (miR-34b and miR-34c) are processed from the same pre-miRNA (BC021736) (He et al., 2007) . In line with published data, we observed that transient expression of miR-34b or miR-34c lowered expression of endogenous Myc ( Figure 2B ). Conversely, transient expression of anti-miR targeting any of the three miR-34 family members enhanced expression of endogenous Myc in U2OS cells, confirming that endogenous miR-34s restrain levels of Myc ( Figure 2B ). SiRNA-mediated depletion of MK5 enhanced expression of a 3 0 UTR reporter construct that contains a wild-type recognition site for miR-34 but had no effect on reporter activity when the miR-34 binding site was mutated ( Figure 2C ). RQ-PCR data showed that depletion of MK5 lowered expression of endogenous miR-34b and miR-34c but had no effect on expression of miR-34a ( Figure 2D ). Furthermore, ectopic expression of constitutively active MK5 enhanced expression of miR-34b and miR-34c ( Figure S2C ). Finally, expression of either miR-34b or miR-34c not only lowered the expression of endogenous Myc but also abolished the (F) Depletion of MK5 increases synthesis of Myc protein. HeLa cells were transfected with control siRNA or siMK5. Two days after transfection, culture medium was replaced by methionine-free medium. Fifteen hours later, 35 S-labeled methionine was added for 60 min. Cells were lysed and immunoprecipitation (IP) input was adjusted using total incorporation. Lysates were immunoprecipitated with a-Myc and control antibodies (rb IgG), precipitates were separated by gel electrophoresis and analyzed by autoradiography. Asterisks indicate unspecific bands.
effect of depletion of MK5 on Myc expression ( Figure 2E ). We concluded that MK5 regulates translation of Myc, since it enhances expression of miR-34b and miR-34c.
The promoter that controls expression of the pre-miRNA BC021736 is a direct target of the p53 tumor suppressor protein (He et al., 2007) . MK5 phosphorylates and activates p53 during oncogene-induced senescence, suggesting that p53 might mediate the effects of MK5 on miR-34b and miR-34c expression (Sun et al., 2007) . However, expression of a carboxyl-terminal fragment of p53 (p53DD), which acts in a dominant-negative manner, elevated basal levels of Myc, but did not diminish upregulation of Myc in response to depletion of MK5 ( Figure 3A) . Also, depletion of MK5 enhanced levels of Myc both in wild-type and p53-deficient HCT116 cells, confirming that the effect of MK5 on Myc levels is independent of p53 ( Figure 7C ). Searching for other transcription factors that might mediate the effect of MK5, we noted that the BC021736 promoter contains consensus binding sites for the FoxO family of transcription factors at positions À185, À1223, À1512, and À1518 ( Figure 3B ). Chromatin immunoprecipitation experiments showed that a hormone-inducible allele of FoxO3a (FoxO3aER[3A] ), in which three Akt-phosphorylation sites have been mutated to alanine, rendering it independent of PI3-kinase dependent signals (see Figure 5A ), bound both at À185 and at À1223 upon addition of 4-hydroxy-tamoxifen (OHT) ( Figure 3C ). Activation of FoxO3aER(3A) upregulated expression of miR-34b and miR-34c, but not miR-34a, demonstrating that activation of FoxO3a is sufficient to induce expression of miR-34b and miR-34c ( Figure 3D ). Conversely, stable 0 UTR of the MYC mRNA (pLSVM3 0 wt) or a derivative, in which the miR-34 binding site is mutated (pLSVM3 0 mut). Cells were cotransfected with control siRNA or siRNA targeting MK5. The plots show the specific luciferase activity as mean + SD (n = 4). (D) MK5 is required for expression of miR-34b/c. Cells were transfected with control siRNA or siRNA targeting MK5, and RNA was isolated 72 hr afterwards. miRNA-specific cDNA was transcribed and levels of miR-34a, miR-34b, and miR-34c were monitored by RQ-PCR. Data are presented as mean + SD (n = 3). (E) MK5 regulates Myc via miR-34b or miR-34c. HCT116 cells were transfected with synthetic miRNA oligonucleotides (34b, 34c) or a scrambled control (Ctr). Cells were cotransfected either with nontargeting control siRNA (C) or with siMK5 (M). Cells were harvested 3 days after transfection, and Myc protein levels were determined by immunoblotting.
expression of the DNA binding domain of FoxO4 (dnFoxO), which is a dominant-negative allele that inhibits all FoxO transcription factors, elevated basal levels of Myc protein in the presence of MK5 and abolished the effect of MK5 depletion on Myc ( Figure 3E ). The data show that one or several FoxO proteins mediate regulation of Myc by MK5.
We have recently demonstrated that miR-34b and miR-34c are upregulated in response to etoposide, an inhibitor of topoisomerase, in a p53-independent manner (Cannell et al., 2010 ).
Exposure of wild-type mouse embryonic fibroblasts to increasing concentrations of etoposide led to an increase in expression of miR-34c, which was diminished in MK5-deficient fibroblasts ( Figure S3A ). Consistently, siRNA-mediated depletion of MK5 abrogated induction of miR-34c, but not miR-34a, in HEK293 cells in response to etoposide ( Figure S3B (A) p53 is not required for regulation of Myc by MK5. U2OS cells were infected with retroviruses encoding a dominant-negative form of p53 (p53DD) or control vector (À). Pools of resistant cells were transfected with siMK5 (M) or a nontargeting siRNA (C). Seventy-two hours after transfection, cells were lysed and immunoblots were probed with the indicated antibodies. Myc protein levels were quantified, and expression levels relative to controls are indicated.
(B) The miR-34b/c promoter contains consensus FoxO binding sites. miR-34b and miR-34c are encoded by one primary transcript (BC021736). Putative FoxO binding sites (indicated by ellipses) were identified at positions À1518, À1512, À1223, and À185 relative to the transcription start site (indicated by an arrow).
(C) FoxO3aER(3A) binds to the BC021736 promoter in vivo. U2OS cells were infected with retroviruses encoding FoxO3aER(3A). Selected cell pools were treated with OHT to activate FoxO3aER(3A). DNA-bound proteins were crosslinked to chromatin, and FoxO3aER(3A) was immunoprecipitated with an antibody directed against ER. Rabbit IgG immune serum was used as IP control (ctr). Immunoprecipitated DNA-fragments were amplified by PCR with primers specific for the putative FoxO3a consensus binding sites (À1518/12, À1223, À185) or a control region. Data are plotted as percentage of input DNA +SD (n = 3). (D) FoxO3aER(3A) induces expression of miR-34b and miR-34c. Cells described in (C) were incubated with OHT (''+OHT'') to activate the fusion protein or with ethanol as solvent control (''ÀOHT''). Forty-eight hours later, RNA was isolated and miR-34 levels were assessed by RQ-PCR in triplicates. Data are presented as mean + SD (n = 3). (E) FoxO proteins are required for regulation of Myc by MK5. U2OS cells were infected with retroviruses encoding a dominant-negative form of FoxO (dnFoxO) or control virus (À). Resistant cell pools were transfected with control siRNA (C) or with siMK5 (M). Seventy-two hours after transfection, cells were lysed and protein levels were detected via immunoblotting. Myc protein levels were quantified; expression levels relative to control cells are indicated below the immunoblots. etoposide downregulated a reporter construct carrying the 3 0 UTR of Myc in control cells, but not in cells expressing a dominant-negative FoxO3a allele ( Figure S3D ). We concluded that MK5 and FoxO proteins are required for induction of miR-34c and downregulation of Myc in response to DNA damage.
To test whether MK5 phosphorylates FoxO transcription factors, we incubated recombinant MK5 with purified proteins containing either FoxO3a or, as a positive control, Hsp27, fused to glutathione S-transferase (GST) in the presence of g 32 P-ATP ( Figure 4A ). MK5 phosphorylated both GST-Hsp27 and GSTFoxO3a, but not GST alone; in addition, we observed that MK5 autophosphorylates, consistent with previous observations (Sun et al., 2007) . Analysis of the phosphorylated GST-FoxO3a protein by mass spectrometry identified several serine residues as targets of MK5 ( Figure 4B ). Analysis of mutant alleles of FoxO3a showed that MK5 phosphorylated FoxO3a predominantly at S215, but that mutation of four of the identified sites was required to essentially abolish phosphorylation of FoxO3a by MK5 (''4A'') ( Figure 4C and data not shown). S215 is conserved among the FoxO family of transcription factors ( Figure 4D ). We raised a polyclonal antiserum that specifically recognizes phosphorylated S215 of FoxO3A and used it to demonstrate that MK5 phosphorylates this residue in vivo ( Figure 4E ). Furthermore, levels of Myc decreased after coexpression of MK5 and wild-type FoxO3a, but not of MK5 and FoxO3aS215A, strongly suggesting that MK5 decreases Myc levels via phosphorylation of FoxO3a at S215.
Consistent with a positive role for MK5 in FoxO3a function, expression of constitutively active MK5 enhanced nuclear localization and DNA binding of wild-type FoxO3a in the presence of serum growth factors, while nuclear relocalization of FoxO3aS215A was unaffected ( Figures 4F and 4G) . Expression of MK5 also accelerated nuclear accumulation of FoxO3a in the presence of the PI3-kinase inhibitor BEZ235 ( Figure 4H ). Nuclear localization of FoxO3aS215A was diminished when PI3-kinase was inhibited and coexpression of MK5 did not restore nuclear accumulation, demonstrating that phosphorylation of S215 by MK5 increases nuclear import or nuclear retention of FoxO3a.
In order to determine whether phosphorylation of FoxO3a by MK5 has effects on the biological properties of FoxO3a, we mutated target sites of MK5 in a FoxO3aER chimeric protein.
To avoid effects of phosphorylation by protein kinase B (Akt), we used FoxO3a(3A) as starting point ( Figure 5A ). Since S253 is targeted by both Akt and MK5, we altered the remaining three sites (S215, S551, and S555) to alanine, thereby creating a mutant that carries six alanine residues instead of three (''6A'' versus ''3A''). We stably expressed both alleles using retroviral infection in U2OS cells and used pools of cells for the subsequent experiments.
Upon addition of OHT, FoxO3aER(3A) rapidly localized to the nucleus, whereas the nuclear accumulation of FoxO3aER(6A) was attenuated, consistent with the phenotype of the FoxO3aS215A mutant ( Figure S4A ). Consistently, in vivo DNA binding of FoxO3aER(6A) to the BC021736 promoter was impaired relative to FoxO3aER(3A) ( Figure S4B ; compare to Figure 3C ). Activation of FoxO3aER(3A) led to rapid downregulation of endogenous Myc expression, whereas downregulation of endogenous Myc was attenuated upon activation of FoxO3aER (6A) ( Figure 5B ). Coexpression of a MYC construct that contains only the coding sequence or the coding sequence plus the 3 0 UTR showed that downregulation of Myc by FoxO3aER(3A) occurs via the 3 0 UTR ( Figure 5C ). Activation of FoxO3aER(3A) upregulated expression of miR-34c and, to a lesser extent, miR-34b, whereas expression of both microRNAs was unaffected upon activation of FoxO3aER(6A) ( Figure 5D ). FoxO3aER(3A) had no effect on expression of miR-34a, arguing that the effects are specific for miR-34b and miR-34c ( Figure 5D ). S215 is part of the DNA binding domain of FoxO3a and contributes a hydrogen bond to DNA binding. To rule out the possibility that the phenotypes of FoxO3aER(6A) were solely due to a reduced DNA binding affinity, we measured expression of CCND1, since repression of CCND1 by FoxO3a occurs independently of direct binding to DNA (Ramaswamy et al., 2002) . FoxO3aER(6A) was impaired in repressing CCND1, arguing that phosphorylation of FoxO3a by MK5 is required for both DNA binding-dependent and -independent functions of FoxO3a ( Figure S4C ).
Activation of FoxO3a induces cell cycle arrest in established cell lines; consistent with this observation, addition of OHT strongly suppressed colony formation of U2OS cells expressing FoxO3aER(3A) ( Figure 5E ). In contrast, activation of FoxO3aER (6A) suppressed colony formation to a lesser extent, suggesting that phosphorylation by MK5 stimulates cell cycle arrest by FoxO3a; consistently, FoxO3aER(6A) had a reduced ability to halt cell cycle progression ( Figure S5 ). To test whether downregulation of Myc is critical for the FoxO3a-induced cell cycle arrest, we determined the cell cycle profile of U2OS cells expressing FoxO3aER(3A) and the MYC constructs described above (see Figure 5C ). Activation of FoxO3aER(3A) led to rapid accumulation in the G1 phase of the cell cycle of either control cells or cells expressing a MYC construct that contains the 3 0 UTR; in contrast, the arrest was attenuated when a MYC construct encompassing only the coding sequence was expressed ( Figure 5F ). Taken together, the data show that (E) MK5 phosphorylates S215 of Foxo3a in vivo. HeLa cells were transfected with expression vectors encoding constitutively active MK5L337G and FoxO3A or FoxO3aS215A as indicated. Twenty-four hours after transfection, cells were harvested, lysates were immunoprecipitated with a-FoxO3a antibodies, and immunoblots were probed with the indicated antibodies. (F) MK5 promotes nuclear accumulation of FoxO3a via S215. HeLa cells were transfected with CMV-driven expression vectors encoding MK5L337G and wildtype FoxO3a (wt) or FoxO3aS215A. Forty-eight hours after transfection, cells were fixed and subjected to immunofluorescence using a FoxO3a or MK5 antibody. downregulation of Myc via the 3 0 UTR is a critical target for the FoxO3a-induced cell cycle arrest.
Ectopic expression of Myc upregulated levels of MK5, suggesting that Myc might also be upstream of MK5 (see Figure 2A) .
Consistently, activation of a conditional MycER protein in U2OS cells led to an upregulation of MK5 mRNA ( Figure 6A ). Furthermore, siRNA-mediated depletion of Myc led to a strong decrease in expression of MK5 protein and mRNA ( Figure 6B ).
(E) FoxO3aER(6A) is impaired in the induction of growth arrest. Cells described in (B) were plated at equal cell numbers and treated for 72 hr with OHT or ethanol (ÀOHT). Medium was replaced by fresh culture medium supplemented with OHT or solvent, respectively, after 48 hr. Cells were fixed and stained with crystal violet. (F) Downregulation of Myc is required for FoxO3a-induced cell cycle arrest. U2OS cells described in (C) were treated with OHT or solvent control (ÀOHT) for 24 hr. Cells were fixed and cell cycle analysis was performed using propidium iodide staining. The numbers indicate the percentage of cells in G1 phase. (D) Depletion of MK5 reduces EFNB1 expression in a p53-dependent manner. Ls174T cells described in (A) and HCT116 cells described in (C) were analyzed for EFNB1 expression. Seventy-two hours after transfections, total RNA was isolated and subjected to RQ-PCR analysis. Data are plotted as mean values + SD (n = 3).
(E) MK5 and Ephrin B1 are expressed in normal colon mucosa but lost in aggressive adenocarcinomas. Tissue sections from a normal colon epithelium (left panels) and from a well-differentiated (middle panels) or from a poorly differentiated adenocarcinoma (right panels) were stained with an MK5 or Ephrin B1 antibody,
The MK5 promoter contains two closely spaced consensus Myc binding sites (E boxes) located at À1066 and À1053 relative to the transcriptional start site ( Figure 6C ). Chromatin immunoprecipitation experiments documented robust binding of endogenous Myc to the MK5 promoter, but not to a control region; the percentage of bound Myc exceeded that bound to the CCND2 promoter, a well-characterized target of Myc ( Figure 6D ). Finally, expression of MK5 was induced in response to addition of growth factors to serum-starved MCF10A cells in a Myc-dependent manner ( Figure 6E ). The data show that MK5 is a direct target gene of Myc, arguing that Myc forms a negative feedback loop with MK5.
To test whether this regulatory circuit is operational in colon carcinoma cells, we expressed MK5 in Ls174T cells; due to mutation in b-catenin, these cells express elevated levels of Myc, which are required to block cell cycle arrest and terminal differentiation . Ectopic expression of either wild-type MK5 or a constitutively active allele of MK5 (MK5L337G) downregulated expression of Myc ( Figure 7A ). Consistent with these observations, ectopic expression of MK5 enhanced expression of CDKN1A (encoding p21Cip1) and MUC2, markers of cell cycle arrest and terminal differentiation, and decreased expression of the stem cell marker LGR5 ( Figures  7A and 7B) . Conversely, depletion of MK5 upregulated Myc expression both in Ls174T and in HCT116 cells (Figures 7A and 7C) .
As noted before, depletion of MK5 enhanced Myc levels in a p53-independent manner, since Myc levels were enhanced by siMK5 in both HCT116-p53 +/+ cells and in their p53 À/À counterparts ( Figure 7C ). Notably, basal Myc levels were elevated in HCT116-p53 À/À cells; therefore depletion of MK5 and loss of p53 resulted in strongly elevated levels of Myc. Since work in other systems has shown that supraphysiological levels of Myc can bind to and regulate a ''transformation-specific'' set of target genes, we were curious as to whether there are target genes of Myc that are specifically regulated by MK5 depletion in a p53 À/À situation (Yustein et al., 2010) . Proliferating colon carcinoma cells express very low levels of p21 and of markers of terminal differentiation, and depletion of MK5 did not further decrease these levels (data not shown). In contrast, depletion of MK5 caused a marginal decrease in expression of EFNB1 mRNA in both +/+ cells but a strong decrease in HCT116-p53 À/À cells ( Figure 7D ). EFNB1 is repressed by Myc and encodes a cell surface-bound ligand (Ephrin B1) that demarcates the boundary between proliferative and nonproliferative cells along the crypt-villus axis van de Wetering et al., 2002) . To test whether MK5 and Ephrin B1 expression are correlated during colorectal tumorigenesis, we used a specific polyclonal antiserum to determine the expression of MK5 in normal colon mucosa and in colorectal carcinomas; in normal colon mucosa, MK5 was expressed along the crypt-villus axis and showed weaker expression at the crypt bases and more prominent expression at the luminal surface ( Figure 7E ). Expression of MK5 was partially maintained in well and moderately differentiated adenocarcinomas (grades 1 and 2), whereas MK5 was downregulated in poorly differentiated adenocarcinomas (grade 3) ( Figure 7E ; Figures S6A and S6B; p = 0.011). Expression of Ephrin B1 closely paralleled that of MK5 ( Figure 7E ). In contrast, Myc expression was weak in normal colon epithelium, but a strong nuclear staining was observed in poorly differentiated adenocarcinomas ( Figure S6C ). To validate these observations in an independent set of samples and test their relevance for colorectal tumor development, we queried a database that contains expression profiles of 396 colorectal cancers from patients for whom the clinical course of the disease is known (Salazar et al., 2010) . Consistent with the immunohistochemical data, expression of MK5 mRNA was significantly downregulated in grade 3 carcinomas relative to the grades 1 and 2 (p = 0.011; Figure 7F ), and low levels of MK5 mRNA were associated with an increased probability for the development of distant metastases (p = 0.015; Figure 7G ). Taken together, the data document a consistent downregulation of MK5, a concomitant loss of Ephrin B1, and an increase in Myc expression during development and progression of colorectal carcinomas.
DISCUSSION
In an siRNA screen of the human kinome, we have identified the protein kinase MK5 as a negative regulator of Myc expression. MK5 phosphorylates and activates the transcription factor FoxO3a and potentially other FoxO factors. Upon phosphorylation, FoxO3a binds to and activates the promoter that controls expression of the precursor RNA of miR-34b and miR-34c, which target the 3 0 UTR of MYC. Expression of MK5 itself is regulated by Myc, since Myc binds to the promoter and activates expression of the MK5 gene; as a result, Myc and MK5 form a negative feedback loop ( Figure 7H) . Notably, expression of MK5 is significantly higher in the tumor cells we studied than in nontransformed WI38 and BJ cells (data not shown), consistent with MK5 being a target of Myc, and indicating that the negative feedback described here is particularly active at elevated Myc levels. Importantly, at least two changes that occur during colorectal carcinogenesis attenuate and possibly disrupt this regulatory circuit. First, the BC021736 promoter contains a CpG island and is silenced by DNA methylation in several colorectal cell lines and primary tumors (Toyota et al., 2008) . Second, expression of MK5 itself is downregulated in colorectal tumors. The reason for downregulation of MK5 is currently unknown. For example, treatment of a panel of colon cancer cell lines with 5-azacytidine and TSA, which activates expression of genes silenced by DNA methylation, has no detectable effect on expression of MK5 (T.R.K., unpublished data). Whether downregulation of MK5 occurs specifically in colorectal tumors or is also found in other tumors is currently being tested.
Both upstream regulators and downstream effectors of MK5 are under intense scrutiny. MK5 has been shown to act downstream of p38 to phosphorylate and thereby activate p53 during oncogene-induced senescence (Sun et al., 2007) . During development, MK5 forms a complex with Erk3 or Erk4 that promotes nuclear export of MK5, protects it from proteasomal degradation, and is essential for kinase activity (Schumacher et al., 2004) . Our siRNA screen did not identify Erk3, Erk4, or any constituent of the p38 kinase pathway as a regulator of Myc. In side-by-side comparisons, the effects of Erk3 or Erk4 depletion and of inhibition of p38 using a chemical inhibitor were small compared to depletion of MK5 (T.R.K., unpublished data). One likely interpretation of these results is that MK5 integrates signals from several upstream kinases that are at least partially redundant under our assay conditions, thereby identifying MK5 as a critical node in Myc regulation. For example, MK5 is essential for downregulation of Myc in response to the DNA damaging agent etoposide. Our previous work has shown that loss of p38 and its downstream kinase MK2 induces a similar failure to downregulate Myc in response to DNA damage (Cannell et al., 2010 ). The precise relationship between p38, MK2, and MK5 in this pathway remains to be elucidated (Cannell et al., 2010) .
Our data identify FoxO proteins as key mediators of Myc regulation by MK5. We show that phosphorylation of S215 in the DNAbinding domain of FoxO and potentially also S551 and S555, which lie within the transactivation domain, is critical for FoxO function. Phosphorylation of S215 by MK5 stimulates both nuclear accumulation and binding of FoxO3a to the BC021736 promoter. Similarly, phosphorylation of the neighboring S209 by Mst1 induces nuclear import and stimulates FoxO3a function; in this respect, MK5 and Mst1 may act in parallel pathways (Lehtinen et al., 2006) . Inspection of the crystal structure of FoxO1 bound to DNA strongly suggests that FoxO3a cannot bind to DNA when S215 is phosphorylated; this has been demonstrated for phosphorylation at S209 (Brent et al., 2008) . Since MK5 promotes in vivo DNA binding of FoxO3a, the most likely interpretation of our data is that FoxO3a is dephosphorylated at S215 in the nucleus in order to bind to DNA. It should be noted, however, that FoxO proteins repress transcription without direct binding to DNA (Ramaswamy et al., 2002) . It is possible, therefore, that phosphorylation by MK5 also serves to modify the spectrum of target genes that is regulated by FoxO proteins.
The promoters of the miR-34 family of microRNAs are targets for the p53 tumor suppressor protein (He et al., 2007) . Consistent with these observations, levels of Myc are elevated when p53 is deleted or inactivated using a dominant-negative allele. Since MK5 regulates Myc levels independently of p53, depletion of MK5 in a p53-deficient situation led to strongly elevated levels of Myc protein. Recent work in an immortalized B cell line has demonstrated that strongly elevated levels of Myc regulate a pathophysiological transcriptional program that is characteristic for Burkitt's lymphoma, a Myc-induced B cell tumor (Yustein et al., 2010) . Consistent with this suggestion, depletion of MK5 regulates EFNB1, a Myc-repressed gene that is involved in the progression of colorectal tumors in p53-deficient but not p53-proficient cells .
While the mechanism of how elevated levels of Myc induce a distinct genetic program remains to be elucidated, it is noteworthy that such levels-in contrast to physiological levelsinduce expression of the Arf tumor suppressor protein (Murphy et al., 2008) . Arf in turn binds both to Myc and its partner protein, Miz1 (Herkert et al., 2010; Qi et al., 2004) . While binding to Arf attenuates the ability of Myc to activate transcription, it promotes assembly of the Myc/Miz1 complex and enhances its ability to repress transcription. Among the target genes of the Myc/Miz1 complex that are suppressed in the presence of Arf are multiple cell surface proteins as well as inhibitors of the Rho GTPase; as a result, Arf-induced assembly of the Myc/Miz1 complex disrupts cell adhesion and promotes apoptosis in p53-proficient cells (Herkert et al., 2010) . Consistent with these observations, the Myc/Miz1 complex promotes invasive behavior and metastasis formation of p53 mutant breast epithelial cells (Chan et al., 2010) . We hypothesize that the induction of Arf alters Myc's transcriptional properties to promote apoptosis in normal cells, and that these changes contribute to invasion and metastasis in an apoptosis-compromised tumor cell.
EXPERIMENTAL PROCEDURES
Cell Culture U2OS, HeLa, HCT116, and Phoenix-Eco cells were cultured in DMEM (2 mM glutamine), and Ls174T cells in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum (Sigma), 100 U/ml penicillin, and 100 mg/ml streptomycin (PAA). Where indicated, 200 nM 4-hydroxy-tamoxifen (OHT; Sigma), 500 nM BEZ235 (Axon Ligands), or cycloheximide (100 mg/ml, Sigma) was added. Cells for FACS analysis were stained with propidium iodide and analyzed using a BD FACS Canto II. Transient transfection and retroviral transduction were performed as described before (Herkert et al., 2010) . siRNA oligonucleotides were from Thermo Scientific Dharmacon, and cells were transfected using Dharmafect1 (Dharmacon) or Lipofectamine RNAiMAX (Invitrogen). miRIDIAN mimics (Dharmacon) and miRCURY LNA miRNA knockdown probes (Exiqon) were transfected using Lipofectamine RNAiMAX. Twenty-four hours after transfection, medium was replaced by fresh culture medium. Seventy-two hours after transfection, cells were harvested and analyzed.
RQ-PCR
Total RNA was isolated with the peqGOLD TriFast reagent (Peqlab) according to the manufacturer's protocol, and cDNA was transcribed using M-MLV reverse transcriptase and random hexanucleotide primers. RQ-PCR analysis was performed in triplicates using the Absolute QPCR SYBR Green Mix (Thermo Scientific) on an Mx3000P System (Stratagene). Data were calculated according to the DDCt relative quantification method. For miRNA analysis, cDNA was transcribed with the miRCURY LNA miRNA cDNA synthesis kit (Exiqon) and miRNAs were amplified with LNA-based miRNA-specific primer sets (Exiqon) according to the manufacturer.
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